Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “outperform” rating restated by investment analysts at Leerink Swann in a note issued to investors on Friday, AnalystRatings.Net reports. They currently have a $18.00 price target on the stock. Leerink Swann’s price objective indicates a potential upside of 233.95% from the stock’s previous close.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded down 1.30% during mid-day trading on Friday, hitting $5.32. Amarin Co. plc has a 52 week low of $5.12 and a 52 week high of $14.97. The stock’s 50-day moving average is currently $5.57. The company’s market cap is $801.7 million.
Amarin Co. plc (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.37 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Amarin Co. plc from $24.00 to $20.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Cazenove cut their price target on shares of Amarin Co. plc from $18.00 to $12.00 in a research note to investors on Wednesday, July 24th. They now have an “overweight” rating on the stock. Finally, analysts at Oppenheimer cut their price target on shares of Amarin Co. plc from $8.00 to $7.00 in a research note to investors on Tuesday, July 9th. They now have a “market perform” rating on the stock.
Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.63.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.